Talk:Eribulin
Add topicLatest comment: 3 months ago by Macrocycle1 in topic Does it have any approvals in Europe - or are any pending decision
| This is the talk page for discussing improvements to the Eribulin article. This is not a forum for general discussion of the subject of the article. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Eribulin.
|
Does it have any approvals in Europe - or are any pending decision
[edit]- Rod57 (talk) 23:21, 30 January 2016 (UTC)
- This is a 10-year old question with no responses, so will respond here although by now Rod57 probably has his answer. Yes, eribulin is approved in the EU for locally advanced or metastatic breast cancer and advanced, unresectable liposarcoma. Please see actual EU approval indications for details of pre-treatment requirements, which are not included here. Macrocycle1 (talk) 23:54, 25 April 2026 (UTC)